Antibody Drug Conjugates (ADC) Market, by Product Type (Adcetris, Kadcyla, and Other Product Types), Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Other Applications), Technology (Cleavable Linker and Non-cleavable Linker), Target Type, End Users and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
The Antibody Drug Conjugates (ADC) market size was estimated at USD 5.78 billion in 2023 and is projected to reach USD 24.53 billion in 2030 at a CAGR of 22.94% during the forecast period 2023-2030.
Antibody-Drug Conjugates (ADCs) are a class of targeted cancer therapies that combine the speciality of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. These therapies are designed to specifically target cancer cells while minimizing damage to healthy cells, which can lead to improved treatment efficacy and reduced side effects compared to traditional chemotherapy. Several ADCs have been approved for use in treating various types of cancers, including breast cancer, lymphoma, and certain types of leukaemia. However, its important to note that ADCs may not be suitable for all types of cancers, and their efficacy and safety depend on factors such as the target antigen, the antibody used, the linker technology, and the cytotoxic payload.
The Antibody-Drug Conjugates (ADCs) market is expected to grow during the forecast period. This growth can be attributed to the growing prevalence of cancer, the increasing geriatric population and increasing research and development activities for the development of novel therapeutics. However, factors such as stringent government regulations, high cost of procedures and lack of funding are expected to hamper the growth of the market during the forecast period.
The COVID-19 pandemic has had a significant impact on the ADC market. On the one hand, the disruptions caused by the pandemic in the drug development activities across the healthcare industry including ADCs impacted the market growth negatively. This was due to factors such as the slowdown in clinical trials, reduced funding for research and development, and the diversion of resources to address the COVID-19 pandemic. On the other hand, the demand for effective cancer treatments has increased significantly during the COVID-19 pandemic and this particular factor has contributed to increased demand for cancer drugs including ADCs and factored the market growth.
The antibody-drug conjugate (ADC) market is expected to grow during the forecast period. This growth can be attributed to several factors. Firstly, the global cancer burden is increasing, and this is expected to drive the demand for new cancer treatments, including ADCs. Moreover, targeted therapies such as ADCs are becoming increasingly popular as compared to traditional treatment methods such as chemotherapy. In addition, the increasing approval of ADCs by regulatory agencies and development of new ADCs is expected to drive the market further during the forecast period. However, the high cost associated with the development as well as treatment, short shelf life, risk of toxicity and competition from other cancer therapies might hamper the growth of the market during the forecast period.
North America to Dominate the Market